C7R-GD2.CART cells / Baylor College of Medicine - LARVOL DELTA

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Baylor College of Medicine | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Initiation date: May 2026 ➔ Aug 2026

Biomarker • Trial initiation date • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

Phase I trial of GD2.CART cells augmented with a constitutively active interleukin-7 receptor for treatment of solid tumors (ASGCT 2026) - P1 | "Methods In a Phase I trial (NCT03635632), patients with extracranial GD2+ solid tumors were treated with escalating doses of C7R-GD2.CART cells (1, 3, and 10 x10^7 cells/m2) with and without preceding standard lymphodepletion...Higher Grade CRS occurred more frequently in the lymphodepletion (LD) cohort (4 of 11) compared to the no LD cohort (0 of 8) but was reversible with early administration of anakinra...D. Absolute regulatory T cells are significantly lower at week 1 in LD group compared to no LD group."

CAR T-Cell Therapy • P1 data • Hematological Malignancies • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • IL7 • IL7R

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) (clinicaltrials.gov) - P1 | N=56 | Recruiting | Sponsor: Baylor College of Medicine | N=37 ➔ 56

Enrollment change • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Embryonal Tumor • Glioma • High Grade Glioma • Oncology • Solid Tumor

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2043 ➔ Apr 2044 | Initiation date: Nov 2025 ➔ May 2026 | Trial primary completion date: Dec 2028 ➔ Apr 2029

Biomarker • Trial completion date • Trial initiation date • Trial primary completion date • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Baylor College of Medicine

Biomarker • New P1 trial • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

C7R-GD2.CAR T Cells for Patients with GD2-expressing Brain Tumors (GAIL-B) (clinicaltrials.gov) - P1 | N=37 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Feb 2039 ➔ Feb 2041 | Trial primary completion date: Feb 2025 ➔ Feb 2027

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Embryonal Tumor • Glioma • Malignant Glioma • Oncology • Solid Tumor

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Active, not recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2039 ➔ May 2038

CAR T-Cell Therapy • Trial completion date • Breast Cancer • CNS Tumor • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Breast Cancer • CNS Tumor • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2038 ➔ Dec 2039 | Trial primary completion date: Jun 2023 ➔ Jun 2024

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Breast Cancer • CNS Tumor • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Neuroendocrine Tumor • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Feb 2038 ➔ Feb 2039 | Trial primary completion date: Feb 2023 ➔ Feb 2025

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Embryonal Tumor • Glioma • Oncology • Solid Tumor

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (clinicaltrials.gov) - P1 | N=94 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Dec 2037 ➔ Dec 2038 | Trial primary completion date: Jun 2022 ➔ Jun 2023

CAR T-Cell Therapy • Trial completion date • Trial primary completion date • Breast Cancer • Ewing Sarcoma • Eye Cancer • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Osteosarcoma • Rhabdomyosarcoma • Sarcoma • Solid Tumor • Uveal Melanoma